Catalyst Wire Dossier Catalyst Wire Dossier

VR 160/20

valsartan/rosuvastatin · LG Life Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VR 160/20, covering 2013-08-07 to 2013-08-07. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg [Phase 1]

See pricing